Table 3.
Patient survival after short-course radiotherapy vs. long-course radiotherapy.
| All Patients | ||||
|---|---|---|---|---|
| Univariate | Multivariate | |||
| HR 1 (95% CI) | p-value | HR 1 (95% CI) | p-value | |
| Overall survival | 0.55 (0.38–0.80) | 0.002 | 0.59 (0.41–0.87) | 0.007 |
| Cancer-specific survival | 0.47 (0.30–0.73) | <0.001 | 0.57 (0.37–0.90) | 0.016 |
| Disease-free survival | 0.54 (0.36–0.80) | 0.002 | 0.62 (0.41–0.93) | 0.021 |
| Distant-recurrence-free survival | 0.52 (0.34–0.79) | 0.002 | 0.58 (0.38–0.90) | 0.014 |
| Local-recurrence-free survival | 0.41 (0.18–0.91) | 0.028 | 0.48 (0.21–1.08) | 0.076 |
| NMAC | ||||
| Univariate | Multivariate | |||
| HR 1 (95% CI) | p-value | HR 1 (95% CI) | p-value | |
| Overall survival | 0.53 (0.35–0.80) | 0.003 | 0.57 (0.37–0.88) | 0.011 |
| Cancer-specific survival | 0.43 (0.26–0.72) | 0.001 | 0.52 (0.30–0.88) | 0.014 |
| Disease-free survival | 0.46 (0.30–0.72) | <0.001 | 0.46 (0.29–0.74) | 0.001 |
| Distant-recurrence-free survival | 0.45 (0.28–0.72) | <0.001 | 0.44 (0.27–0.72) | 0.001 |
| Local-recurrence-free survival | 0.39 (0.17–0.93) | 0.033 | 0.45 (0.19–1.07) | 0.070 |
| MAC | ||||
| Univariate | Multivariate | |||
| HR 1 (95% CI) | p-value | HR 1 (95% CI) | p-value | |
| Overall survival | 0.86 (0.37–2.03) | 0.736 | 0.50 (0.19–1.30) | 0.157 |
| Cancer-specific survival | 0.94 (0.39–2.27) | 0.896 | 0.54 (0.28–2.34) | 0.209 |
| Disease-free survival | 1.55 (0.62–3.86) | 0.347 | 1.22 (0.45–3.29) | 0.696 |
| Distant-recurrence-free survival | 1.49 (0.60–3.72) | 0.393 | 1.33 (0.50–3.52) | 0.572 |
| Local-recurrence-free survival | 0.49 (0.04–5.36) | 0.555 | - 2 | - 2 |
1 Long-course radiotherapy is reference. Covariates entered in the multivariate model were sex, age, TNM stage, the grade of differentiation and perioperative chemotherapy. 2 Multivariate analysis was unavailable due to too few cases.